Takeda Launches the First and Only Orexin Medicine ORZEYFUL for Narcolepsy Type 1 in the US
Takeda, a biopharma company has officially launched ORZEYFUL (oveporexton) in the United States, introducing the first and only approved orexin receptor agonist for adults living with narcolepsy type 1 (NT1). The medicine is now available by prescription, offering a new treatment approach that targets the underlying biological cause of the disease rather than focusing only on individual symptoms.
The launch follows the US Food and Drug Administration's approval of ORZEYFUL in August 2026. Its commercial availability began after the drug received Schedule IV controlled substance classification, allowing healthcare providers to prescribe it to eligible adult patients.
Narcolepsy type 1 is a chronic q disorder associated with a loss of orexin, a brain chemical that helps regulate wakefulness and sleep. The condition can cause excessive daytime sleepiness, sudden loss of muscle control known as cataplexy, cognitive difficulties and disrupted nighttime sleep.
These symptoms can affect several aspects of daily life, including professional responsibilities, education, personal relationships and routine activities. Patients often need to plan their schedules around sleep attacks and periods of reduced alertness.
According to Takeda, NT1 affects approximately 3 million people worldwide, including around 120,000 people in the United States. Despite its impact, the condition remains significantly underdiagnosed. Only an estimated 50% of US patients have received a diagnosis, and the diagnostic process can take an average of 10 years.
Existing treatments have helped manage certain symptoms, but more than half of treated patients continue to experience symptoms. This highlights the need for therapies that address the underlying disease mechanism.
ORZEYFUL introduces a different approach through its mechanism of action. It is an oral orexin receptor 2 (OX2R) agonist that selectively activates OX2R to restore orexin signalling. This activity promotes wakefulness and helps reduce abnormal REM-sleep-related symptoms, including cataplexy.
Clinical trial findings showed improvements across several symptoms associated with NT1. Takeda's approach aims to provide broader disease management by addressing both daytime and nighttime challenges experienced by patients.
The medicine is available through Accredo Specialty Pharmacy, part of Evernorth Health Services. Takeda is also providing patient support programmes to help eligible adults understand insurance coverage requirements and available financial assistance options.
However, ORZEYFUL comes with important safety considerations. The most common adverse reactions include insomnia, increased urinary frequency, urinary urgency and excessive saliva production. Clinical studies also reported creatine phosphokinase elevations in some patients.
The medicine is contraindicated in patients taking strong CYP3A inhibitors and carries a risk of abuse and misuse because it is classified as a Schedule IV controlled substance. Healthcare providers must assess patients appropriately and monitor them during treatment.
The US launch also strengthens Takeda's broader investment in orexin science. The company is developing additional oral orexin agonists, including TAK-360 for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, along with TAK-495.
For Takeda, ORZEYFUL represents an important commercial and scientific milestone in sleep medicine. Its availability creates a new treatment option for adults with NT1 and strengthens the company's position in a therapeutic area where many patients continue to experience unmet treatment needs.
About Takeda
Takeda is a Japan-based global biopharmaceutical company focused on developing treatments across gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. The company operates in approximately 80 countries and regions, with a focus on research-driven innovation and improving patient outcomes.
Reference:
https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-narcolepsy-type-1-us/
https://www.towardshealthcare.com/insights/drugs-market-sizing


